Invion Ltd
ASX:IVX

Watchlist Manager
Invion Ltd Logo
Invion Ltd
ASX:IVX
Watchlist
Price: 0.11 AUD Market Closed
Market Cap: 8.5m AUD

Relative Value

The Relative Value of one IVX stock under the Base Case scenario is hidden AUD. Compared to the current market price of 0.11 AUD, Invion Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IVX Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
92
vs Industry
24
Median 3Y
9.4
Median 5Y
15.7
Industry
2.5
vs History
vs Industry
Median 3Y
-24
Median 5Y
-34.4
Industry
21.2
vs History
vs Industry
Median 3Y
-17.3
Median 5Y
-17.3
Industry
16.3
vs History
vs Industry
Median 3Y
-8.3
Median 5Y
-8.3
Industry
23.8
vs History
95
vs Industry
71
Median 3Y
2.2
Median 5Y
3.7
Industry
2.1
vs History
92
vs Industry
25
Median 3Y
8.9
Median 5Y
15.3
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.2
vs History
vs Industry
Median 3Y
-22
Median 5Y
-29.7
Industry
12.5
vs History
vs Industry
Median 3Y
-22
Median 5Y
-29.7
Industry
15.9
vs History
vs Industry
Median 3Y
-16.5
Median 5Y
-16.5
Industry
14.6
vs History
vs Industry
Median 3Y
-7.3
Median 5Y
-7.3
Industry
17.2
vs History
95
vs Industry
72
Median 3Y
2.4
Median 5Y
5.5
Industry
1.8

Multiples Across Competitors

IVX Competitors Multiples
Invion Ltd Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Invion Ltd
ASX:IVX
8.5m AUD 5.8 -1.3 -1.1 -1.1
US
Eli Lilly and Co
NYSE:LLY
734.9B USD 15 66.2 35.6 38.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
366.6B USD 4.1 16.8 12.3 16.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.4 18.6 12.9 14.8
CH
Roche Holding AG
SIX:ROG
208.1B CHF 3.4 25.1 9.4 11
CH
Novartis AG
SIX:NOVN
188.4B CHF 4.4 18.3 10.8 14.5
UK
AstraZeneca PLC
LSE:AZN
158.5B GBP 4 28 130.7 197.1
US
Merck & Co Inc
NYSE:MRK
199B USD 3.1 11.4 8.5 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
137.5B USD 2.2 17.4 7.5 10.5
P/E Multiple
Earnings Growth PEG
AU
Invion Ltd
ASX:IVX
Average P/E: 25.2
Negative Multiple: -1.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.2
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.8
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.6
18%
1
CH
Roche Holding AG
SIX:ROG
25.1
32%
0.8
CH
Novartis AG
SIX:NOVN
18.3
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.4
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.4
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Invion Ltd
ASX:IVX
Average EV/EBITDA: 433.5
Negative Multiple: -1.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.6
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.7
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.5
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Invion Ltd
ASX:IVX
Average EV/EBIT: 1 867.1
Negative Multiple: -1.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.8
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.1
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.8
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
14.5
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.1
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.3
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
10%
1.1